The study included 309 HIV-infected pregnant women receiving a lamivudine-containing antiretroviral regimen from week 25 of gestational age until 6 months postpartum, during breastfeeding. Twenty-seven of them (8.7%) were hepatitis B virus surface antigen (HBsAg) positive; at baseline, hepatitis B virus (HBV) DNA levels >3 log10 IU/mL (with a median level of 6.2 log10 IU/mL) were found in 10 women, who at one, three and six months postpartum had median levels of 5.2 log10 IU/mL, 4.5 log10 IU/mL and 2.8 log10 IU/mL, respectively. Twenty-four of the 30 breast milk samples evaluated had undetectable HBV DNA and the other six had values between 15 and 155 IU/mL. Median lamivudine concentrations were 1070 ng/mL in serum and 684 ng/mL in breast milk. Among the 24 HBV-exposed children with available samples, 16 always tested negative, four had a transient infection, one had an undetermined status and three (12.5%) first tested positive at Month 12 or Month 24. Among the children born to the HBV-uninfected mothers of the same cohort, the rate of HBsAg positivity at 12-24 months was 2% (4/196). Our finding of the absence of significative levels of HBV DNA in the breast milk of co-infected mothers supports the present recommendations for breastfeeding in HBV-infected women. Horizontal transmission can be hypothesized for the infections detected in children at 12-24 months. Children born to HBV-positive mothers remained at higher risk of postnatal HBV acquisition compared to those born to HBV-negative women. © 2014 John Wiley & Sons Ltd.

Pirillo, M., Scarcella, P., Andreotti, M., Jere, H., Buonomo, E., Sagno, J., et al. (2015). Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. JOURNAL OF VIRAL HEPATITIS, 22(3), 289-296 [10.1111/jvh.12301].

Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding

SCARCELLA, PAOLA;BUONOMO, ERSILIA;MANCINELLI, SANDRO;PALOMBI, LEONARDO;
2015-01-01

Abstract

The study included 309 HIV-infected pregnant women receiving a lamivudine-containing antiretroviral regimen from week 25 of gestational age until 6 months postpartum, during breastfeeding. Twenty-seven of them (8.7%) were hepatitis B virus surface antigen (HBsAg) positive; at baseline, hepatitis B virus (HBV) DNA levels >3 log10 IU/mL (with a median level of 6.2 log10 IU/mL) were found in 10 women, who at one, three and six months postpartum had median levels of 5.2 log10 IU/mL, 4.5 log10 IU/mL and 2.8 log10 IU/mL, respectively. Twenty-four of the 30 breast milk samples evaluated had undetectable HBV DNA and the other six had values between 15 and 155 IU/mL. Median lamivudine concentrations were 1070 ng/mL in serum and 684 ng/mL in breast milk. Among the 24 HBV-exposed children with available samples, 16 always tested negative, four had a transient infection, one had an undetermined status and three (12.5%) first tested positive at Month 12 or Month 24. Among the children born to the HBV-uninfected mothers of the same cohort, the rate of HBsAg positivity at 12-24 months was 2% (4/196). Our finding of the absence of significative levels of HBV DNA in the breast milk of co-infected mothers supports the present recommendations for breastfeeding in HBV-infected women. Horizontal transmission can be hypothesized for the infections detected in children at 12-24 months. Children born to HBV-positive mothers remained at higher risk of postnatal HBV acquisition compared to those born to HBV-negative women. © 2014 John Wiley & Sons Ltd.
2015
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/42 - IGIENE GENERALE E APPLICATA
English
Con Impact Factor ISI
Africa; Breastfeeding; Hepatitis B virus; HIV; Lamivudine; Perinatal transmission; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infections; Hepatitis B; Humans; Lamivudine; Male; Pregnancy; Risk Factors; Young Adult; Breast Feeding; Coinfection; Hepatitis B virus; Infectious Disease Transmission, Vertical; Virology; Infectious Diseases; Hepatology
Pirillo, M., Scarcella, P., Andreotti, M., Jere, H., Buonomo, E., Sagno, J., et al. (2015). Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. JOURNAL OF VIRAL HEPATITIS, 22(3), 289-296 [10.1111/jvh.12301].
Pirillo, M; Scarcella, P; Andreotti, M; Jere, H; Buonomo, E; Sagno, J; Amici, R; Mancini, M; Leone, P; Ceffa, S; Mancinelli, S; Marazzi, M; Vella, S; ...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
2015 Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 92.34 kB
Formato Adobe PDF
92.34 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/131043
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact